"Antibodies, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunoglobulins produced in response to VIRAL ANTIGENS.
| Descriptor ID |
D000914
|
| MeSH Number(s) |
D12.776.124.486.485.114.254 D12.776.124.790.651.114.254 D12.776.377.715.548.114.254
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Viral".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Viral".
This graph shows the total number of publications written about "Antibodies, Viral" by people in this website by year, and whether "Antibodies, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 5 | 4 | 9 |
| 1995 | 5 | 3 | 8 |
| 1996 | 4 | 7 | 11 |
| 1997 | 1 | 4 | 5 |
| 1998 | 3 | 10 | 13 |
| 1999 | 3 | 7 | 10 |
| 2000 | 2 | 5 | 7 |
| 2001 | 1 | 5 | 6 |
| 2002 | 7 | 15 | 22 |
| 2003 | 6 | 9 | 15 |
| 2004 | 3 | 13 | 16 |
| 2005 | 10 | 15 | 25 |
| 2006 | 6 | 7 | 13 |
| 2007 | 2 | 12 | 14 |
| 2008 | 7 | 14 | 21 |
| 2009 | 5 | 10 | 15 |
| 2010 | 3 | 9 | 12 |
| 2011 | 9 | 14 | 23 |
| 2012 | 10 | 13 | 23 |
| 2013 | 16 | 8 | 24 |
| 2014 | 14 | 15 | 29 |
| 2015 | 22 | 12 | 34 |
| 2016 | 12 | 19 | 31 |
| 2017 | 14 | 15 | 29 |
| 2018 | 21 | 13 | 34 |
| 2019 | 13 | 12 | 25 |
| 2020 | 32 | 21 | 53 |
| 2021 | 36 | 39 | 75 |
| 2022 | 8 | 63 | 71 |
| 2023 | 5 | 55 | 60 |
| 2024 | 19 | 14 | 33 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Viral" by people in Profiles.
-
Bivalent Omicron BA.4/BA.5 BNT162b2 Vaccine in 6-Month- to <12-Year-Olds. J Pediatric Infect Dis Soc. 2024 Aug 24; 13(8):421-429.
-
Comparison of uridine and N1-methylpseudouridine mRNA platforms in development of an Andes virus vaccine. Nat Commun. 2024 Jul 30; 15(1):6421.
-
Anti-SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021-June 2022. J Infect Dis. 2024 Jul 25; 230(1):45-54.
-
Multi-antigen intranasal vaccine protects against challenge with sarbecoviruses and prevents transmission in hamsters. Nat Commun. 2024 Jul 23; 15(1):6193.
-
Hybrid Immunity and SARS-CoV-2 Antibodies: Results of the HEROES-RECOVER Prospective Cohort Study. Clin Infect Dis. 2024 Jul 19; 79(1):96-107.
-
Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement system Commun Biol. 2024 07 17; 7(1):871.
-
Antibody Response to Symptomatic Infection With SARS-CoV-2 Omicron Variant Viruses, December 2021-June 2022. Influenza Other Respir Viruses. 2024 Jul; 18(7):e13339.
-
Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19. Clin Infect Dis. 2024 Jun 14; 78(6):1490-1503.
-
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 Jun 14; 78(6):1757-1768.
-
Functional and structural basis of human parainfluenza virus type 3 neutralization with human monoclonal antibodies. Nat Microbiol. 2024 Aug; 9(8):2128-2143.